| Culture and behaviour in the English National Health Service: overview of lessons from a large multimethod study M Dixon-Woods, R Baker, K Charles, J Dawson, G Jerzembek, G Martin, ... BMJ quality & safety 23 (2), 106-115, 2014 | 613 | 2014 |
| How collaborative are quality improvement collaboratives: a qualitative study in stroke care P Carter, P Ozieranski, S McNicol, M Power, M Dixon-Woods Implementation Science 9, 1-11, 2014 | 67 | 2014 |
| Exposing drug industry funding of UK patient organisations P Ozieranski, E Rickard, S Mulinari Bmj 365, 2019 | 62 | 2019 |
| Disclosure of payments by pharmaceutical companies to healthcare professionals in the UK: analysis of the Association of the British Pharmaceutical Industry’s Disclosure UK … S Mulinari, P Ozieranski BMJ open 8 (10), e023094, 2018 | 50 | 2018 |
| Walkrounds in practice: corrupting or enhancing a quality improvement intervention? A qualitative study G Martin, P Ozieranski, J Willars, L McKee, K Charles, J Minion, ... The Joint Commission Journal on Quality and Patient Safety 40 (7), 303-310, 2014 | 50 | 2014 |
| Pharmaceutical lobbying under postcommunism: universal or country-specific methods of securing state drug reimbursement in Poland? P Ozierański, M McKee, L King Health Economics, Policy and Law 7 (2), 175-195, 2012 | 49 | 2012 |
| Analysis of pharmaceutical industry payments to UK health care organizations in 2015 P Ozieranski, M Csanadi, E Rickard, J Tchilingirian, S Mulinari JAMA Network Open 2 (6), e196253-e196253, 2019 | 44 | 2019 |
| A pill too hard to swallow: how the NHS is limiting access to high priced drugs J Gornall, A Hoey, P Ozieranski Bmj 354, 2016 | 43 | 2016 |
| The politics of health technology assessment in Poland P Ozieranski, M McKee, L King Health policy 108 (2-3), 178-193, 2012 | 42 | 2012 |
| Pharmaceutical industry self-regulation and non-transparency: country and company level analysis of payments to healthcare professionals in seven European countries S Mulinari, L Martinon, PA Jachiet, P Ozieranski Health Policy 125 (7), 915-922, 2021 | 40 | 2021 |
| Five years of pharmaceutical industry funding of patient organisations in Sweden: Cross-sectional study of companies, patient organisations and drugs S Mulinari, A Vilhelmsson, E Rickard, P Ozieranski PLoS One 15 (6), e0235021, 2020 | 34 | 2020 |
| Failure of responsive regulation? pharmaceutical marketing, corporate impression management and off-label promotion of enzalutamide in Europe S Mulinari, C Davis, P Ozieranski Journal of White Collar and Corporate Crime 2 (2), 69-80, 2021 | 33 | 2021 |
| When health technology assessment is confidential and experts have no power: the case of Hungary M Csanádi, O Löblová, P Ozierański, A Harsányi, Z Kaló, M McKee, ... Health Economics, Policy and Law 14 (2), 162-181, 2019 | 33 | 2019 |
| The emerging social science literature on health technology assessment: a narrative review O Löblová, T Trayanov, M Csanádi, P Ozierański Value in Health 23 (1), 3-9, 2020 | 28 | 2020 |
| Evaluation of financial and nonfinancial conflicts of interest and quality of evidence underlying psoriatic arthritis clinical practice guidelines: analysis of personal … H Mamada, A Murayama, S Kamamoto, Y Kaneda, M Yoshida, S Sugiura, ... Arthritis Care & Research 75 (6), 1278-1286, 2023 | 27 | 2023 |
| Accessibility and quality of drug company disclosures of payments to healthcare professionals and organisations in 37 countries: a European policy review P Ozieranski, L Martinon, PA Jachiet, S Mulinari BMJ open 11 (12), e053138, 2021 | 27 | 2021 |
| Evaluating the transparency of pharmaceutical company disclosure of payments to patient organisations in the UK E Rickard, P Ozieranski, S Mulinari Health Policy 123 (12), 1244-1250, 2019 | 25 | 2019 |
| Governing drug reimbursement policy in Poland: The role of the state, civil society, and the private sector P Ozieranski, LP King Theory and Society 46, 577-610, 2017 | 23 | 2017 |
| Capitalizing on transparency: Commercial surveillance and pharmaceutical marketing after the Physician Sunshine Act S Mulinari, P Ozieranski Big Data & Society 9 (1), 20539517211069631, 2022 | 22 | 2022 |
| International comparison of pharmaceutical industry payment disclosures in the UK and Japan: implications for self-regulation, public regulation, and transparency P Ozieranski, H Saito, E Rickard, S Mulinari, A Ozaki Globalization and Health 19 (1), 14, 2023 | 20 | 2023 |
Shai MulinariSociology, Lund University.Dirección de correo verificada de soc.lu.se
